| Patents for C07D 491 - Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups , , or (29,726) |
|---|
| 04/03/2003 | CA2461089A1 Pharmaceutically acceptable salts of 20(s)-camptothecins |
| 04/02/2003 | WO2002030891A1 Aliphatic nitrogenous five-membered ring compounds |
| 04/02/2003 | EP1297835A1 Benzo[b]pyrano[3,2-h]acridin-7-one derivatives, processes for their preparation and pharmaceutical compositions thereof |
| 04/02/2003 | EP1297108A2 Cell lines and cell-based assays for identification of androgen receptor modulators |
| 04/02/2003 | EP1296988A1 Azepino 4,5-b]pyrano 3,2-e]indoles |
| 04/02/2003 | EP1296987A1 Compounds for treating impaired fundic relaxation |
| 04/02/2003 | EP1296975A1 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors |
| 04/02/2003 | EP0770081B1 Heterocycle-condensed morphinoid derivatives |
| 04/02/2003 | CN1407970A Urea compounds having muscarinic receptor antagonist activity |
| 04/02/2003 | CN1104434C Optical pure analogs of camptothecinum and composition and use thereof |
| 04/02/2003 | CN1104409C Aminotetralone derivatives and process for producing same |
| 04/01/2003 | US6541505 Inhibiting the activity of Factor Xa; treating a disease state associated with a physiologically detrimental excess amount of thrombin. |
| 04/01/2003 | US6541504 Modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation. |
| 04/01/2003 | US6541503 Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threonine kinase inhibitors |
| 04/01/2003 | US6541502 Treatment of disorders associated with dopamine dysregulation such as schizophrenia |
| 04/01/2003 | US6541501 2-(aminomethyl)-tetrahydro-9-oxa-1,3-diaza-cyclopenta[a]-naphthalenyl derivatives with antipsychotic activity |
| 04/01/2003 | US6541481 Substituted bicyclic derivatives useful as anticancer agents |
| 04/01/2003 | US6541470 Have a potent antiviral activity against picornaviruses and rotaviruses. |
| 03/27/2003 | WO2003025017A1 Cytokine receptor |
| 03/27/2003 | WO2003024973A1 Spirocyclic-6,7-dihydro-5h-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines |
| 03/27/2003 | WO2003024971A1 6,7-dihydro-5h-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines |
| 03/27/2003 | WO2003024970A1 Compounds which inhibit the release of inflammatory cytokines |
| 03/27/2003 | WO2003024941A1 Naphthalene compounds and use thereof as drugs |
| 03/27/2003 | WO2003024936A1 Substituted pyrazolo compounds for the treatment of inflammation |
| 03/27/2003 | WO2003024899A2 CYCLIC HYDROXAMIC ACIDS AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-α CONVERTING ENZYME (TACE) |
| 03/27/2003 | WO2003024448A2 Inhibitors of histone deacetylase |
| 03/27/2003 | WO2003002715A3 Compositions and methods for labeling oligonucleotides |
| 03/27/2003 | WO2002098854A3 Process for preparing chiral diol sulfones and dihydroxy acid hmg coa reductase inhibitors |
| 03/27/2003 | WO2002078628A3 Cyanamide, alkoxyamino, and urea derivatives of 1,3-benzodiazapines as hiv reverse transcriptase inhibitors |
| 03/27/2003 | WO2002060879A3 Bacterial gyrase inhibitors and uses thereof |
| 03/27/2003 | WO2002050023A3 Synthesis of pancrastistatin |
| 03/27/2003 | WO2002026229A1 Airway mucus secretion inhibitors |
| 03/27/2003 | WO2002013802A3 Method of treating estrogen receptor positive carcinoma |
| 03/27/2003 | US20030060623 Having microtubule-stabilizing effects and cytotoxic activity against rapidly proliferating cells, such as, tunior cells or other hyperproliferative cellular disease |
| 03/27/2003 | US20030060462 Therapeutic compounds |
| 03/27/2003 | CA2465978A1 Inhibitors of histone deacetylase |
| 03/27/2003 | CA2461073A1 6,7-dihydro-5h-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines |
| 03/27/2003 | CA2461072A1 Compounds which inhibit the release of inflammatory cytokines |
| 03/27/2003 | CA2461071A1 Spirocyclic-6,7-dihydro-5h-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines |
| 03/27/2003 | CA2460151A1 Cytokine receptor |
| 03/27/2003 | CA2423945A1 Restrainers of airway mucus secretion |
| 03/26/2003 | EP1294728A1 HMG-CoA REDUCTASE INHIBITORS AND METHOD |
| 03/26/2003 | EP1294725A2 Multicyclic compounds and the use thereof as inhibitors of parp, vegfr2 and mlk3 enzymes |
| 03/26/2003 | EP1294702A1 Benzodiazepine derivatives as app modulators |
| 03/26/2003 | EP1294700A2 Benzhydryl derivatives |
| 03/26/2003 | EP0977748B1 Substituted benzopyran derivatives for the treatment of inflammation |
| 03/26/2003 | CN1406243A Memno peptides, a process for their preparation and their use |
| 03/26/2003 | CN1406230A 2,4-di (hetero-) arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents |
| 03/26/2003 | CN1406225A Quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists |
| 03/26/2003 | CN1103772C Novel 2,3-disubstituted-4 (3H)-quinazolinone |
| 03/26/2003 | CN1103769C Tricyclic amine derivatives |
| 03/25/2003 | US6538009 Pyrazole derivatives as anti-inflammatory/analgesic agents |
| 03/25/2003 | US6538004 Potassium channel modulators relax smooth muscle cells and inhibit bladder contractions; treating nervous, eating, cardiovascular, gastrointestinal, and sexual disorders |
| 03/25/2003 | US6538003 Pyridopyranoazepine derivatives, their preparation and their therapeutic application |
| 03/25/2003 | US6538000 9-(3-chloro-4-hydroxyphenyl)-5,6,7,9-tetrahydropyrazolo(5,1-b) quinazoline-8(4H)-one;for cardiovascular disorders |
| 03/25/2003 | US6537999 Pyrimidine derivatives and methods of making and using these derivatives |
| 03/21/2003 | WO2002026230A1 Remedies for inflammatory bowel diseases |
| 03/21/2003 | CA2423423A1 Medecines of ulcerative colitis |
| 03/20/2003 | WO2003022856A1 Substituted 7-aza[2.2.1] bicycloheptanes for the treatment of diseases |
| 03/20/2003 | WO2003022852A2 Furo-and thienopyrimidine derivatives as angiogenesis inhibitors |
| 03/20/2003 | WO2003022848A2 Process for the preparation of diketopyrrolopyrroles |
| 03/20/2003 | WO2003022847A2 Process for the direct preparation of pyrrolo[3,4-c]pyrroles |
| 03/20/2003 | WO2003022801A1 Reverse hydroxamic acid derivatives |
| 03/20/2003 | WO2003022785A2 Synthesis of enantiomerically pure amino-substituted fused bicyclic rings |
| 03/20/2003 | WO2002100319A3 Method for cleaning hard gelatine capsules |
| 03/20/2003 | WO2002074758A3 Novel amines as histamine-3 receptor ligands and their therapeutic applications |
| 03/20/2003 | WO2002012188B1 Indole compounds useful for the treatment of cancer |
| 03/20/2003 | US20030055257 Water-soluble rhodamine dye conjugates |
| 03/20/2003 | US20030055251 Useful as neuropeptide Y receptor antagonists and as agents for therapy of cardiovascular disorders, central nervous system disorders, metabolic diseases |
| 03/20/2003 | US20030055074 For use in therapy of psychic and neurological disorders |
| 03/20/2003 | US20030055068 Pyrazole compounds useful as protein kinase inhibitors |
| 03/20/2003 | US20030055050 CRF receptor antagonists and methods relating thereto |
| 03/20/2003 | US20030055044 Administering pyrazole derivative for inhibiting GSK-3 or Aurora activity in a patient |
| 03/20/2003 | US20030055035 Useful in hyperpolarizing cell membranes, opening potassium channels, relaxing smooth muscle cells, and inhibiting bladder contractions |
| 03/20/2003 | US20030054957 Combining functional material to be precipitated as nanoscale particles and surface active material in compressed carbon dioxide phase with density of 0.1 g/cc, rapidly depressurizing compressed phase, thereby precipitating dispersed function |
| 03/20/2003 | US20030054291 Multilayer; radiation transparent substrate, recording media, reflective layer and protective coatings |
| 03/20/2003 | CA2460075A1 Substituted 7-aza[2.2.1] bicycloheptanes for the treatment of diseases |
| 03/20/2003 | CA2457710A1 Process for the direct preparation of pyrrolo¬3,4-c|pyrroles |
| 03/20/2003 | CA2456614A1 Synthesis of enantiomerically pure amino-substituted fused bicyclic rings |
| 03/19/2003 | EP1292576A1 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity |
| 03/19/2003 | EP0931082B1 Nodulisporic acid derivatives |
| 03/19/2003 | EP0799228B1 3-aryl-tetronic acid derivatives, the production thereof and the use thereof as anti-parasitic agents |
| 03/19/2003 | EP0711350B1 Clavulanic acid dehydrogenase, preparation and use for the production of clavulanic acid |
| 03/19/2003 | CN1404472A Dihydro-1,3,5-triazine amine derivatives and their therapeutic uses |
| 03/18/2003 | US6534653 Such as methyl(1S,2R,6S,7R,9R)-4,4-dimethyl-8((S)-1-phenylethyl))-3,5-dioxa-8 -azatricyclo(5.2.1.00,0)decane-9-carboxylate |
| 03/18/2003 | US6534522 Subtype-selective NMDA receptor ligands and the use thereof |
| 03/18/2003 | CA2422758A1 3-spiro-cyanin fluorochromes and their use in bioassays |
| 03/13/2003 | WO2003020700A2 SUBSTITUTED INDENO[1,2-c]ISOQUINOLINE DERIVATIVES AND METHODS OF USE THEREOF |
| 03/13/2003 | WO2003020698A2 Protein tyrosine kinase inhibitors |
| 03/13/2003 | WO2003020252A2 Treatment of chronic myelogenous leukemia, resistant or intolerant to sti571, involving homoharringtonine alone or combined with other agents |
| 03/13/2003 | WO2002096359A3 Piperazine pentanamide hiv protease inhibitors |
| 03/13/2003 | WO2002088080A3 Dual inhibitors of pde 7 and pde 4 |
| 03/13/2003 | WO2002087513A3 Fused heterocyclic inhibitors of phosphodiesterase (pde) 7 |
| 03/13/2003 | WO2002068388A3 Acylated piperidine derivatives as melanocortin-4 receptor agonists |
| 03/13/2003 | WO2002022563A1 Urea derivative and adhesive-molecule inhibitor containing the same as active ingredient |
| 03/13/2003 | US20030050304 Therapeutic compounds |
| 03/13/2003 | US20030050301 A drug mixture additionally comprising an antihypertensive agent or it's prodrug and a carrier, vehicle or diluent |
| 03/13/2003 | US20030050281 Analogs of galanthamine and lycoramine as modulators of nicotinic receptors |
| 03/13/2003 | CA2459822A1 Treatment of chronic myelogenous leukemia, resistant or intolerant to sti571, involving homoharringtonine alone or combined with other agents |
| 03/13/2003 | CA2457534A1 Substituted indeno[1,2-c]isoquinoline derivatives and methods of use thereof |